Evidence map›Paper›PMID 34430070›Full record

ArticleTremor and other hyperkinetic movements (New York, N.Y.)2021

Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.

Maximilian A Schwittay, Andreas Steinbrecher, Elmar Lobsien

Abstract readCase Reports
In one paragraph

Article in Tremor and other hyperkinetic movements (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maximilian A SchwittayDepartment of Neurology, Helios Klinikum Erfurt, DE.
Andreas SteinbrecherDepartment of Neurology, Helios Klinikum Erfurt, DE.
Elmar LobsienDepartment of Neurology, Helios Klinikum Erfurt, DE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tourette syndrome (TS) manifests with motor and vocal tics that can reach disabling intensity. Established therapies may show insufficient relief or side effects. Cannabinoids have demonstrated therapeutic potential in small studies. This report presents buccal Nabiximols "as required" in the treatment of tics in TS. Case report: A 25-year-old man presented with stigmatizing motor and phonic tics after cessation of daily Cannabis use. After Tiaprid 300 mg per day had shown no sufficient effect a trial of Nabiximols reduced tics by >90%. Discussion: Nabiximols could be an adjunct treatment in TS for situations were tics are severly disabling.

Indexed as

CannabidiolTicsTourette SyndromeAdultDronabinolDrug CombinationsHumansMaleCannabidiolDronabinolDrug CombinationsnabiximolsCannabinoidshyperkinetic movement disorderneurodevelopmental disorderNeuropharmacologyon demand treatmentTicTourette

Identifiers

PMID34430070
PMCPMC8344952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.